Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus CLONAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus CLONAZEPAM.
CENTRAX vs CLONAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Enhances GABA-A receptor inhibitory neurotransmission by binding to benzodiazepine binding site, increasing frequency of chloride channel opening, leading to neuronal hyperpolarization.
10-30 mg orally, 3-4 times daily.
0.5 mg orally three times daily; maximum 20 mg/day
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Clinical Note
moderateClonazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Fluconazole
Terminal elimination half-life: 19-60 hours (mean 30-40 hours); clinical context: long-acting benzodiazepine, allows once or twice daily dosing; accumulation occurs with repeated use.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal: 50-70% as metabolites (mostly glucuronide conjugates), <2% unchanged; fecal: 10-20%; biliary: minor.
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Fluconazole can be decreased when combined with Clonazepam."